Partner Fund Management LP Position in Edwards Lifesciences Corp (EW) Has Decreased by $16.14 Million as Share Value Rose

April 26, 2018 - By Peter Erickson

Edwards Lifesciences Corporation (NYSE:EW) Logo

Christopher Medlock James decreased its stake in Edwards Lifesciences Corp (EW) by 13.89% based on its latest 2017Q4 regulatory filing with the SEC. Partner Fund Management Lp sold 144,141 shares as the company’s stock rose 22.78% while stock markets declined. The hedge fund run by Christopher Medlock James held 893,283 shares of the industrial specialties company at the end of 2017Q4, valued at $100.68M, down from 1.04 million at the end of the previous reported quarter. Partner Fund Management Lp who had been investing in Edwards Lifesciences Corp for a number of months, seems to be less bullish one the $27.29B market cap company. The stock increased 0.07% or $0.09 during the last trading session, reaching $129.61. About 1.99 million shares traded or 45.13% up from the average. Edwards Lifesciences Corporation (NYSE:EW) has risen 44.06% since April 26, 2017 and is uptrending. It has outperformed by 32.51% the S&P500.

Partner Fund Management Lp, which manages about $4.22B US Long portfolio, upped its stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 193,750 shares to 2.61M shares, valued at $155.78M in 2017Q4, according to the filing. It also increased its holding in Humana Inc (NYSE:HUM) by 93,290 shares in the quarter, for a total of 294,480 shares, and has risen its stake in Molina Healthcare Inc (NYSE:MOH).

Edwards Lifesciences Corporation (NYSE:EW) Ratings Coverage

Among 16 analysts covering Edwards Lifesciences (NYSE:EW), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Edwards Lifesciences had 29 analyst reports since November 5, 2017 according to SRatingsIntel. BMO Capital Markets maintained Edwards Lifesciences Corporation (NYSE:EW) on Thursday, December 7 with “Buy” rating. Canaccord Genuity maintained Edwards Lifesciences Corporation (NYSE:EW) on Thursday, March 22 with “Buy” rating. The stock has “Buy” rating by SunTrust on Wednesday, January 31. Jefferies maintained it with “Buy” rating and $150.0 target in Thursday, February 1 report. As per Thursday, December 7, the company rating was maintained by Jefferies. The stock of Edwards Lifesciences Corporation (NYSE:EW) earned “Overweight” rating by Barclays Capital on Friday, February 2. Cowen & Co maintained the shares of EW in report on Tuesday, March 20 with “Buy” rating. BMO Capital Markets maintained the shares of EW in report on Wednesday, January 17 with “Buy” rating. Canaccord Genuity maintained the stock with “Buy” rating in Wednesday, April 25 report. Cowen & Co maintained the shares of EW in report on Friday, December 8 with “Buy” rating.

Edwards Lifesciences Corporation (NYSE:EW) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: